Abstract
Dual EGFR/erbB2 inhibition is an attractive therapeutic strategy for epithelial tumors, as ligand-induced erbB2/EGFR heterodimerization triggers potent proliferative and survival signals. Here we show that a small molecule, GW572016, potently inhibits both EGFR and erbB2 tyrosine kinases leading to growth arrest and/or apoptosis in EGFR and erbB2-dependent tumor cell lines. GW572016 markedly reduced tyrosine phosphorylation of EGFR and erbB2, and inhibited activation of Erk1/2 and AKT, downstream effectors of proliferation and cell survival, respectively. Complete inhibition of activated AKT in erbB2 overexpressing cells correlated with a 23-fold increase in apoptosis compared with vehicle controls. EGF, often elevated in cancer patients, did not reverse the inhibitory effects of GW572016. These observations were reproduced in vivo, where GW572016 treatment inhibited activation of EGFR, erbB2, Erk1/2 and AKT in human tumor xenografts. Erk1/2 and AKT represent potential biomarkers to assess the clinical activity of GW572016. Inhibition of activated AKT in EGFR or erbB2-dependent tumors by GW572016 may lead to tumor regressions when used as a monotherapy, or may enhance the anti-tumor activity of chemotherapeutics, since constitutive activation of AKT has been linked to chemo-resistance.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J, Raspall G, Giralt J, Rosello J, Nicholson RI, Mendelsohn J, Baselga J . 2001 Cancer Res. 61: 6500–6510
Bacus SS, Zelnich CR, Plowman G, Yarden Y . 1994 Am. J. Clin. Path. 102: Suppl S13–S24
Brognard J, Clark AS, Dennis PA . 2001 Cancer Res. 61: 3986–3997
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter J, Paton V, Shak S, Lieberman G, Slamon D . 1999 J. Clin. Oncol. 17: 2639–2648
Cockerill S, Stubberfield C, Stables J, Carter M, Guntrip S, Smith K, McKeown S, Shaw R, Topley P, Thomsen L, Affleck K, Jowett A, Hayes D, Willson M, Woollard P, Spalding D . 2001 Bioorganic Med. Chem. Letts. 11: 1401–1405
Daly RJ . 1999 Growth Factors 16: 255–263
Di Fiore PP, Pierce JH, Fleming TP, Hazan R, Ullrich A, King CR, Schlessinger J, Aaronson SA . 1987 Cell 51: 1063–1070
DiMarco E, Pierce JH, Fleming TP, Kraus MH, Molloy CJ, Aaronson SA, DiFiore PP . 1989 Oncogene 4: 831–838
Earp HS, Dawson TL, Li X, Yu H . 1995 Breast Cancer Res. Treat. 35: 115–132
Egan SE, Weinberg RA . 1993 Nature 365: 781–783
Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL, Hook KE, Keller PR, Leopold WR, Loo JA, McNamara DJ, Nelson JM, Sherwood V, Smaill JB, Trumpp-Kallmeyer S, Dobrusin EM . 1998 Proc. Natl. Acad. Sci. USA 95: 12022–12027
Goldstein NL, Prewett M, Zuklys K, Rockwell P, Mendelsohn J . 1995 Clin. Cancer Res. 1: 1311–1318
Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SD, Tweardy DJ . 1998 J. Natl. Cancer Inst. 90: 824–832
Graus-Porta D, Beerli RR, Daly JM, Hynes NE . 1997 EMBO J. 16: 1647–1655
Harris RA, Eichholtz TJ, Hiles JD, Page MJ, O'Hare MJ . 1999 Int. J. Cancer 80: 477–484
Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, Kohno M . 1999 Oncogene 18: 813–822
Howell GM, Humphrey LE, Awwad RA, Wang D, Koterba A, Periyasamy B, Yang J, Li W, Willson JK, Ziober BL, Coleman K, Carboni J, Lynch M, Brattain MG . 1998 J. Biol. Chem. 273: 9214–9223
Hudziak RM, Schlessinger J, Ullrich A . 1987 Proc. Natl. Acad. Sci. USA 84: 7159–7163
Janes PW, Daly RJ, deFazio A, Sutherland R . 1994 Oncogene 9: 3601–3608
Jiang D, Yang H, Willson JK, Liang J, Humphrey LE, Zborowska E, Wang D, Foster J, Fan R, Brattain MG . 1998 J. Biol. Chem. 273: 31471–31479
Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE, Yarden Y . 1996 EMBO J. 15: 254–264
Kavanaugh WM, Williams LT . 1994 Science 266: 1862–1865
Klapper LN, Kirschbaum MH, Sela M, Yarden Y . 2000 Adv. Cancer Res. 77: 25–79
Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve R, Haynes NE . 2000 Mol. Cell. Biol. 20: 3210–3223
Levkowitz G, Klapper LN, Tzahar E, Freywald A, Sela M, Yarden Y . 1996 Oncogene 12: 1117–1125
Levitzki A, Gazit A . 1995 Science 267: 1782–1787
Luttrell DK, Lee TJ, Lansing TJ, Crosby RM, Jung KD, Willard D, Luther M, Rodriguez J, Berman J, Gilmer TM . 1994 Proc. Natl. Acad. Sci. USA 91: 83–87
Mendelsohn J . 1997 Clin. Cancer Res. 3: 2703–2707
Olayioye MA, Graus-Porta D, Beerli RR, Rohrer J, Gay B, Hynes NE . 1998 Mol. Cell. Biol. 18: 5042–5051
Qian XL, Dougall WC, Frei ZZ, Greene MI . 1995 Oncogene 10: 211–219
Pulverer BJ, Kyriakis JM, Avruch J, Nikolakaki E, Woodgett JR . 1991 Nature 363: 83–85
Reise DJ, Stern DF . 1998 Bioessays 20: 41–48
Rusnak DW, Affleck K, Cockerill SG, Stubberfield C, Harris R, Page M, Smith KJ, Guntrip SB, Carter MC, Shaw RJ, Jowett A, Stables J, Topley P, Wood ER, Brignola PS, Kadwell SH, Reep BR, Mullin RJ, Alligood KJ, Keith BR, Crosby RM, Murray DM, Knight WB, Gilmer TM, Lackey K . 2001a Cancer Res. 61: 7196–7203
Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Glennon K, Knight WB, Mullin RJ, Gilmer TM . 2001b Mol. Cancer Therap. 1: 85–94
Salomon DD, Brandt R, Ciardiello F, Normanno N . 1995 Crit. Rev. Oncol. Hematol. 19: 183–232
Scott GK, Dodson JM, Montgomery PA, Johnson RM, Sarup JC, Wong WL, Ullrich A, Shepard HM, Benz CC . 1991 J. Biol. Chem. 266: 14300–14305
Sibilia M, Wagner EF . 1995 Science 269: 234–238
Slamon DJ, Clark SG, Wong WJ, Levin A, Ullrich A, McGuire WL . 1987 Science 235: 177–182
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF . 1989 Science 244: 707–712
Stern DF, Kamps MP . 1988 EMBO J. 7: 995–1001
Tari AM, Lopez-Berestein G . 2000 Int. J. Cancer 86: 295–297
Tenzer A, Zingg D, Rocha S, Hemmings B, Fabbro D, Glanzmann C, Schubiger PA, Bodis S, Pruschy M . 2001 Cancer Res. 61: 8203–8210
Thakkar H, Chen X, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwadiwe N, Srivastava RK . 2001 Oncogene 20: 6073–6083
Threadgill DW, Dlugosz AA, Hansen LA, Tennenbaum T, Lichti U, Yee D, Lamantia C, Mourton T, Herrup K, Harris RC, Barnard JA, Yuspa SH, Coffey RJ, Magnuson T . 1995 Science 269: 230–234
Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y . 1996 Mol. Cell. Biol. 16: 5276–5287
Ullrich A, Schlessinger J . 1990 Cell 61: 203–212
Wada T, Qian XL, Greene MI . 1990 Cell 61: 1339–1347
Ye D, Mendelsohn J, Fan Z . 1999 Oncogene 18: 731–738
Acknowledgements
The authors would like to thank Tona Gilmer, Karen Lackey, Blaine Knight, Eddie Wood, and Nelson Rhodes for helpful discussions.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Xia, W., Mullin, R., Keith, B. et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21, 6255–6263 (2002). https://doi.org/10.1038/sj.onc.1205794
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205794
Keywords
This article is cited by
-
Cell surface protein aggregation triggers endocytosis to maintain plasma membrane proteostasis
Nature Communications (2023)
-
Extended transit compartment model to describe tumor delay using Coxian distribution
Scientific Reports (2022)
-
Dual targeting micelles loaded with paclitaxel and lapatinib for combinational therapy of brain metastases from breast cancer
Scientific Reports (2022)
-
A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer
BMC Cancer (2021)
-
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
npj Breast Cancer (2021)